( e specifically the mean HbA1c level am...)A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients,Health

e specifically, the mean HbA1c level among treated patients was reduced 0.43%, 0.94% (p<0.05), 1.09% (p<0.05), 1.12% (p<0.05), 1.21% (p<0.05), and 1.14% in months 1, 2, 3, 4, 5, and 6 post-treatment, respectively. In contrast, the mean HbA1c levels of the placebo group ranged from a reduction of 0.1% to an increase of 1.0% over the same period. In addition to the HbA1c reductions, the data demonstrated decreases in fasting blood glucose levels as well as improvements in glucose tolerance over a six month period following treatment with E1-I.N.T.(TM). Trends in increased insulin levels as measured with an oral glucose tolerance test were also observed, particularly in patients where the HbA1c levels decreased over 1% with E1-I.N.T.(TM) therapy. These data are consistent with the increased glucose control observed in diabetes animal models where a short treatment with E1-I.N.T.(TM) resulted in a sustained increase in beta cell mass and function. These clinical improvements, including HbA1c reductions greater than 1% in patients six month post-treatment, highlight the potential that E1-I.N.T.(TM) therapy could provide patients significant clinical benefit in excess of 6 months.

Safety and Tolerability Findings:

There were no serious adverse events noted during the study. As described in Transition's press release of March 5th, 2007, the most common adverse events reported by patients receiving E1-I.N.T.(TM), were nausea, diarrhea, headaches and vomiting which were generally mild to moderate in nature. The majority of these adverse events were reported during the treatment period with the occurrence of adverse events in the post-treatment phase being similar in both the treated and placebo groups.

Next Steps:

In this study, the tolerable dosing levels of E1-I.N.T.(TM) and the efficacy parameters to be employed in future clinical studies were established. Building upon these sustained efficacy findings, the next steps in clinical development w
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy